A Phase 1/2 Study of Vadastuximab Talirine Administered in Sequence With Allogeneic Hematopoietic Stem Cell Transplant in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 28 Oct 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Vadastuximab talirine (Primary) ; Fludarabine; Melphalan; Methotrexate; Tacrolimus
Indications Acute myeloid leukaemia
Focus Adverse reactions; Therapeutic Use
Sponsors Seagen

06 Mar 2017 According to a Seattle Genetics media release, the US FDA has lifted clinical hold on this trial. However, the company will not resume this trial given the challenges of developing therapies in this specific setting.
06 Mar 2017 According to a Seattle Genetics media release, status changed from suspended to discontinued.
27 Dec 2016 According to a Seattle Genetics media release, the US FDA has placed a partial clinical hold on several early stage trials of vadastuxumab talirine in acute myeloid leukemia, including this trial, due to potential risk of hepatotoxicity.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com